Editorial commentary: Future of transcatheter mitral valve interventions for secondary mitral regurgitation
- PMID: 33188901
- DOI: 10.1016/j.tcm.2020.11.001
Editorial commentary: Future of transcatheter mitral valve interventions for secondary mitral regurgitation
Conflict of interest statement
Disclosures The department of Cardiology of the Leiden University Medical Center received research grants from Abbott Vascular, Bayer, Bioventrix, Biotronik, Boston Scientific, Edwards Lifesciences, GE Healthcare and Medtronic. Victoria Delgado received speaker fees from Abbott Vascular, Edward Lifesciences, GE Healthcare, MSD, Medtronic and Novartis. Jeroen J Bax received speaker fees from Abbott Vascular. The remaining author reports no conflicts.
Comment on
-
Transcatheter treatment of functional mitral valve regurgitation.Trends Cardiovasc Med. 2021 Nov;31(8):487-494. doi: 10.1016/j.tcm.2020.10.006. Epub 2020 Oct 15. Trends Cardiovasc Med. 2021. PMID: 33069900 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
